I'm a provider
You will be redirected to myBlue. Would you like to continue?
Please wait while you are redirected.
Please enter a username and password.
DESCRIPTIONMany skin diseases respond to treatment with medications applied directly to the skin, or medications taken orally. In some difficult to treat skin disorders, ultraviolet light is prescribed as therapy. While in general, ultraviolet light is damaging to the skin, some diseases may show benefit from ultraviolet exposure.
Circadian rhythm disorders: The human body functions slightly differently at different times of day and night, according to an approximate 24 hour cycle. For example, the body's level of the natural hormone, cortisol, rises and falls at different times of the day. As well, a person's performance at some tasks is better at certain times of the day. Circadian rhythm is a term for the body's natural 24-hour cycle. Disturbance of the natural rhythm may show up as problems sleeping and waking at usual times.
To make the skin even more sensitive to the ultraviolet rays, a pill called a psoralen is sometimes taken (the opposite effect of a sunscreen). Once the psoralen is absorbed into the body, it makes the skin cells more susceptible to Ultraviolet-A(UV-A) light. The combination of psoralen pill and UV-A light is called photochemotherapy, or PUVA. The light is usually shone inside a booth, either in a hospital or clinic, to part or all of the body. While it is not known exactly how it works, there is first mild damage to the skin (like a sunburn) followed by healing of the skin later. Ultraviolet-B (UV-B) is a different wavelength of light used to treat some of the same skin disorders as UV-A. UV-B booths can be installed in the home setting.
Goeckerman treatment involves either painting effected areas with a solution of coal tar, or covering them with crude coal tar ointment and subsequently irradiating with ultraviolet (UV-B) light.
POLICYThe procedures and services addressed in this medical policy may only be rendered or ordered by Dermatologists.
PUVA treatment is covered for the following conditions only when they have not responded to other forms of conservative treatment:
Goeckerman therapy is covered in the treatment of:
Ultraviolet light therapy is covered two to three times per week for eight weeks or a maximum of 24 treatments. Medical necessity must be established for claims reporting more than 24 treatments.
Home ultraviolet light is a covered service when provided to patients who have chronic or recalcitrant disease requiring long term maintenance exceeding four (4) months. Home therapy should be limited to UVB.
Home phototherapy is appropriate for the following diagnoses:
Eligibility for a home therapy device is contingent upon compliance with the following criteria:
Blue Cross & Blue Shield of Mississippi will limit payment to the most appropriate device that adequately meets the needs of the patient.
Phototherapy (including light boxes, panels, or visors) is not covered for the following conditions because light therapy has not been shown to be more effective than placebo for:
PUVA therapy is not covered when any of the following exists:
The coverage guidelines outlined in the Medical Policy Manual should not be used in lieu of the Member's specific benefit plan language.
Evaluation and management services reported on the same date as ultraviolet light therapy are appropriate in the following circumstances:
Investigative is defined as the use of any treatment procedure, facility, equipment, drug, device, or supply not yet recognized as a generally accepted standard of good medical practice for the treatment of the condition being treated and; therefore, is not considered medically necessary. For the definition of Investigative, “generally accepted standards of medical practice” means standards that are based on credible scientific evidence published in peer-reviewed medical literature generally recognized by the relevant medical community, and physician specialty society recommendations, and the views of medical practitioners practicing in relevant clinical areas and any other relevant factors. In order for equipment, devices, drugs or supplies [i.e, technologies], to be considered not investigative, the technology must have final approval from the appropriate governmental bodies, and scientific evidence must permit conclusions concerning the effect of the technology on health outcomes, and the technology must improve the net health outcome, and the technology must be as beneficial as any established alternative and the improvement must be attainable outside the testing/investigational setting.
POLICY HISTORY7/1993: Approved by Medical Policy Advisory Committee (MPAC)
4/1997: Investigational indication of seasonal affective disorder approved by (MPAC)
8/1999: Revisions approved by MPAC
2/11/2002: Appeal statement deleted from Policy Exception section, investigational definition added
5/2/2002: Type of Service and Place of Service deleted
6/12/2002: ICD-9 procedure codes 99.82 and 99.83 added
2/19/2003: Description of E0202 and E0690 updated to be consistent with AMA
3/11/2003: Code Reference section updated
6/27/2003: HCPCS A4633, A4634 deleted, replacement included in rental
12/6/2004: Code Reference section updated, CPT 97028 added, ICD-9 diagnosis code 202.1 5th digit added and description revised, ICD-9 diagnosis 696.8, 698.9 added, HCPCS A4633, S9098 added, HCPCS A4639, E0690 deleted, HCPCS E0691, E0692, E0693, E0694 effective date added
10/24/2006: Policy reviewed, seasonal affective disorder changed from investigational to medically necessary.
10/30/2006: Code reference section updated. ICD-9 diagnosis code 296.99 added to table.
03/16/2011: The policy statement regarding home ultraviolet light was revised to remove the requirement for a documented response to UVL. It was changed to state the following: Home ultraviolet light is a covered service when provided to patients who have chronic or recalcitrant disease requiring long term maintenance exceeding four (4) months.
08/02/2011: Revised policy to remove references to seasonal affective disorder (SAD).
04/12/2012: Policy reviewed; no changes.
12/06/2012: Policy archived.
03/21/2013: Medical policy reactivated and updated. Policy statement updated to state that the procedures and services addressed in this medical policy may only be rendered or ordered by Dermatologists.
02/20/2014: Policy reviewed; no changes.
08/28/2015: Code Reference section updated for ICD-10.
06/06/2016: Policy number added. Investigative definition updated in Policy Guidelines section.
SOURCE(S)Teicher MH, et al, Am J Psychiatry 1996, Aug 153(8):1110-1.
Journal of American Academy of Dermatology 1994; 31:643-8)
June/July 1997 Medicare B Health Resource
Blue Cross Blue Shield Association policy #1.01.04
CODE REFERENCEThis may not be a comprehensive list of procedure codes applicable to this policy.
The code(s) listed below are ONLY medically necessary if the procedure is performed according to the "Policy" section of this document.